Baseline immunity to SARS-CoV-2 (COVID-19) in the German population.

• Conditions: COVID19; U07.1; COVID-19, virus identified

• Registration Number: DRKS00029693
• Lead Sponsor: Institut für Virologie/Universitätsklinikum Bonn

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2022-07-19
• Results First Posted: 2022-10-12
• Study Completion: 2022-12-31
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 15941

Inclusion Criteria

Randomised invitation based on participation in the payback panel
- Randomised invitation for participation via telephone
- Ability to answer a questionaire in german

Exclusion Criteria

None

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The primary endpoint is the prevalence of anti-SARS/CoV-2 seropositive individuals in the study population, defined as the number of individuals with positive laboratory findings for S or N antibodies divided by the total number of study participants.

Secondary Outcome Measures

Name	Time	Method
Secondary endpoints are.<br>(i) the underdetection rate, defined as the number of individuals with a positive laboratory result (in the study) but without known prior exposure to SARS-CoV-2 (before the study was conducted), divided by the total number of study participants,<br>(ii) the vaccination underreporting rate, defined as the difference between the publicly reported vaccination rate and the study vaccination rate, which is the ratio of the reported vaccinations in the questionnaire to the total number of study participants.